Peptides with anticancer potential discovered in new study
Researchers have found peptides that bind to chains of ubiquitin proteins in cancer cells, suggesting they could be used as a therapeutic strategy.
List view / Grid view
Researchers have found peptides that bind to chains of ubiquitin proteins in cancer cells, suggesting they could be used as a therapeutic strategy.
US researchers, using genome sequencing, put forward the Nile rat as the new model organism for diabetes research.
A new pre-clinical study has utilised nanoparticles to attach immune-activating molecules to cancer cells.
NIH researchers who intravenously delivered a cancer vaccine to mice report that it increased the number of T cells able to combat tumours.
Looking for solutions to resolve your unique challenges? We offer several customized products and services to move your discovery forward.
German researchers have designed peptides that bind to amyloidogenic proteins linked to Alzheimer’s and type 2 diabetes, to effectively suppress both cytotoxic amyloid aggregation and amyloid cross-accelerating interactions.
A research team at the University of Exeter have found that the unexplored genomic control regions yield the key to finding causes of Congenital Hyperinsulinism.
Using DNA barcoding to track cancer cells through time, scientists have shown that the cells have diverse abilities to escape the immune system.
Scientists have generated polygenic risk scores for developing paediatric steroid sensitive nephrotic syndrome (pSSNS), a kidney disease in children.
Streamline your cancer research using this guide that groups antibodies against critical cancer biomarkers according to biomarker type or tissue type.
The researchers used a zebrafish model to test mutations in Mycn, a gene which causes Feingold syndrome.
The study’s findings have important implications for better understanding the neurological basis for ASD and developing effective therapies for patients.
Tune in to this podcast to hear experts discuss 3D cell models, organoids and the automation of complex cell assays.
The molecules, called SGDGs, may lead to new ways to treat age-related neurological diseases.
In this Q&A, Dr Stephen Jones from Vilnius University Life Sciences Center discusses his work on the recent developments in genome editing tools at the university.